Ethyl trans-2-(bromomethyl)cyclopropanecarboxylate | 38506-15-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl trans-2-(bromomethyl)cyclopropanecarboxylate
• 英文别名: Ethyl (1R,2R)-2-(bromomethyl)cyclopropane-1-carboxylate
• CAS: 38506-15-9
• 化学式: C₇H₁₁BrO₂
• 分子量: 207.067
• InChiKey: XAUNGMQKDDMMQW-NTSWFWBYSA-N

物化性质

• 沸点：
  218.0±13.0 °C(Predicted)
• 密度：
  1.462±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Ethyl trans-2-(bromomethyl)cyclopropanecarboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 8.0h， 生成 trans-2-(propylaminomethyl)cyclopropanecarboxylic acid
  参考文献：
  名称：

  受限构象的γ-氨基丁酸类似物的合成。第2部分。2-（氨基甲基）环烷羧酸

  摘要：

  绕γ-氨基丁酸的C（2）–C（3）键旋转受限的类似物的合成，即顺式和反式-2-（氨基甲基）-环丙烷和-环丁烷羧酸和反式-2-（氨基甲基）环己烷羧酸被描述。

  DOI：

  10.1039/p19820002563
• 作为产物：
  描述：

  反-1,2-环丙烷二羧酸二乙酯 在 sodium hydroxide 、 硼烷四氢呋喃络合物 、 三溴化磷 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 Ethyl trans-2-(bromomethyl)cyclopropanecarboxylate
  参考文献：
  名称：

  受限构象的γ-氨基丁酸类似物的合成。第1部分。2-氨基环烷基乙酸

  摘要：

  描述了作为受限构象的γ-氨基丁酸类似物的顺式和反式-2-氨基环丙基，-环丁基，-环戊基和-环己基乙酸的合成。质谱证据完全支持构型异构体的立体化学分配。

  DOI：

  10.1039/p19820002553

文献信息

• Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands
  申请人：——

  公开号：US20030229066A1

  公开（公告）日：2003-12-11

  The invention relates to heterocyclic substituted urea derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  该发明涉及对多巴胺D3受体显示选择性结合的杂环取代脲衍生物。另一方面，该发明涉及一种用于治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，患者需要接受此类治疗，包括向受试者施用所述化合物的治疗有效量以缓解此类疾病。可以用这些化合物治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑障碍、睡眠障碍、昼夜节律障碍和情绪障碍。该发明还涉及所述化合物的制备过程以及将其作为多巴胺D3受体成像剂的方法。
• Transformations of ethoxycarbonyl-substituted but-3-enyl and cyclopropylmethyl radicals: characterisation by e.s.r. spectroscopy
  作者：Alwyn G. Davies、Bernard T. Golding、Robyn S. Hay-Motherwell、Samson Mwesigye-Kibende、D. N. Ramakrishna Rao、Martyn C. R. Symons

  DOI：10.1039/c39880000378

  日期：——

  Ethoxycarbonyl-substituted but-3-enyl and cyclopropylmethyl radicals were generated from the corresponding halides by treatment with tributyltin and triethylsilyl radicals in cyclopropane solution; the radicals were characterised by e.s.r. spectroscopy and the rearrangement at –40 °C of the 3-ethoxycarbonylbut-1-enyl radical to the 1-ethoxycarbonylbut-1-enyl radical was demonstrated.

  用三丁基锡和三乙基甲硅烷基在环丙烷溶液中处理，由相应的卤化物生成乙氧基羰基取代的丁-3-烯基和环丙基甲基。通过esr光谱对自由基进行了表征，并证明了在–40°C下3-乙氧基羰基丁-1-烯基重排为1-乙氧基羰基丁-1-烯基。
• Intramolecular cyclopropylmethylation via non-classical carbocations
  作者：M. Skvorcova、A. Jirgensons

  DOI：10.1039/c7ob01721a

  日期：——

  Cyclopropyl–cyclopropyl rearrangement can be achieved selectively by intramolecular trapping of cyclopropylmethyl carbenium ions with an internal nucleophile. This can be exploited as a useful method for the introduction of a cyclopropyl group into complex molecules using readily accessible disubstituted cyclopropane intermediates.

  环丙基-环丙基重排可通过分子内捕获带有内部亲核试剂的环丙基甲基碳鎓离子来实现。可以将其用作使用容易获得的二取代的环丙烷中间体将环丙基引入复杂分子的有用方法。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070142351A1

  公开（公告）日：2007-06-21

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其显示对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与需要该治疗的患者的多巴胺D3受体活性有关，包括向受试者投予所述化合物的治疗有效量以缓解该疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合征、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律障碍和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物用作多巴胺D3受体成像剂的方法。